| Literature DB >> 27919279 |
Yuji Shimizu1,2, Hiroyuki Yoshimine3, Mako Nagayoshi4, Koichiro Kadota4, Kensuke Takahashi3, Kiyohiro Izumino5, Kenichiro Inoue5, Takahiro Maeda4,6.
Abstract
BACKGROUND: Our previous study showed that height is inversely associated with the risk of stroke in middle-aged Japanese men, particularly in those with a low body mass index (BMI). Since height is regarded as a surrogate maker of childhood social and physical condition, while BMI may reflect primarily on the current physical condition, a detailed analysis of those with a lower BMI may elucidate the effects of childhood conditions. On the other hand, dyslipidemia is recognized as a prominent risk factor for cardiovascular disease. However, no studies have reported on the association between height and dyslipidemia accounting for BMI status.Entities:
Mesh:
Year: 2016 PMID: 27919279 PMCID: PMC5139031 DOI: 10.1186/s40101-016-0119-1
Source DB: PubMed Journal: J Physiol Anthropol ISSN: 1880-6791 Impact factor: 2.867
Age-adjusted characteristics of study population in relation to height
| Height quartiles | |||||
|---|---|---|---|---|---|
| Q1 (low) | Q2 | Q3 | Q4 (high) |
| |
| Median height, cm | 164.2 | 168.4 | 172.1 | 177.2 | |
| No. of participants | 750 | 753 | 752 | 761 | |
| Age, years | 49.3 ± 6.9 | 47.6 ± 6.9 | 46.7 ± 7.1 | 45.8 ± 6.5 | |
| Systolic blood pressure, mmHg | 126 | 126 | 126 | 127 | 0.446 |
| Diastolic blood pressure, mmHg | 80 | 80 | 81 | 81 | 0.220 |
| Body mass index, kg/m2 | 24.1 | 24.1 | 24.2 | 24.1 | 0.993 |
| Current drinker, % | 69.5 | 72.1 | 75.8 | 75.5 | 0.019 |
| Current smoker, % | 38.4 | 37.7 | 40.1 | 37.4 | 0.696 |
| Anti-hypertensive medication, % | 16.0 | 12.0 | 14.8 | 14.2 | 0.130 |
| Glucose lowering medication, % | 3.8 | 3.5 | 4.4 | 3.9 | 0.851 |
| Lipid lowering medication, % | 9.1 | 8.6 | 7.4 | 6.4 | 0.179 |
| Serum HDL-cholesterol (HDL), mg/dL | 59 | 58 | 58 | 57 | 0.246 |
| Serum LDL-cholestreol (LDL), mg/dL | 129 | 128 | 127 | 126 | 0.212 |
| Serum triglycerides (TG), mg/dL | 133 | 132 | 126 | 135 | 0.365 |
| Blood sugar, mg/dL | 100 | 101 | 102 | 101 | 0.346 |
| Serum creatinine, mg/dL | 0.85 | 0.87 | 0.91 | 0.90 | 0.002 |
Age: mean ± standard deviation. Height quartiles are <166.7 cm for Q1, 166.7–170.3 cm for Q2, 170.4–174.2 cm for Q3, >174.2 cm for Q4
Odds ratios (ORs) and 95% confidence intervals (CIs) for dyslipidemia in relation to height for total subjects, stratified by BMI status
| Height quartiles |
| 1 SD increment of height (5.7 cm) | ||||
|---|---|---|---|---|---|---|
| Q1 (low) | Q2 | Q3 | Q4 (high) | |||
| Total subjects | ||||||
| No. of paticipants | 750 | 753 | 752 | 761 | ||
| No. of cases (%) | 426 (56.8) | 392 (52.1) | 395 (52.5) | 375 (49.3) | ||
| Age-adjusted ORs | 1.00 | 0.86 (0.70, 1.05) | 0.89 (0.73, 1.09) | 0.80 (0.65, 0.98) | 0.055 | 0.95 (0.88, 1.02) |
| Multivariable ORs | 1.00 | 0.84 (0.68, 1.04) | 0.86 (0.69, 1.07) | 0.78 (0.62, 0.97) | 0.040 | 0.94 (0.87, 1.01) |
| BMI < 25 kg/m2 | ||||||
| No. of paticipants | 485 | 489 | 483 | 495 | ||
| No. of cases (%) | 237 (48.9) | 221 (45.2) | 199 (41.2) | 192 (38.8) | ||
| Age-adjusted ORs | 1.00 | 0.91 (0.71, 1.17) | 0.79 (0.61, 1.02) | 0.74 (0.57, 0.95) | 0.011 | 0.91 (0.83, 0.99) |
| Multivariable ORs | 1.00 | 0.86 (0.66, 1.12) | 0.75 (0.57, 0.98) | 0.72 (0.55, 0.95) | 0.011 | 0.90 (0.82, 0.99) |
| BMI ≥ 25 kg/m2 | ||||||
| No. of paticipants | 265 | 264 | 269 | 266 | ||
| No. of cases (%) | 189 (71.3) | 171 (64.8) | 196 (72.9) | 183 (68.8) | ||
| Age-adjusted ORs | 1.00 | 0.75 (0.52, 1.08) | 1.10 (0.75, 1.61) | 0.91 (0.62, 1.32) | 0.865 | 1.02 (0.89, 1.16) |
| Multivariable ORs | 1.00 | 0.77 (0.53, 1.12) | 1.11 (0.75, 1.63) | 0.91 (0.62, 1.34) | 0.860 | 1.02 (0.89, 1.17) |
Dyslipidemia is defined as TG ≥ 150 mg/dL and/or LDL-choresterol ≥ 140 mg/dL, and/or HDL-cholesterol < 40 mg/dL, and/or lipid lowering medication use. Multivariable ORs adjusted further for age, systolic blood pressure, antihypertensive medication use, body mass index, smoking status, alcohol consumption, blood sugar, glucose lowering medication use, and serum creatinine. Height quartiles are <166.7 cm for Q1, 166.7–170.3 cm for Q2, 170.4–174.2 cm for Q3, >174.2 cm for Q4
Fig. 1Association between short stature and high BMI as bone marrow activity. a Area where potential effects of childhood circumstances can be elucidated. b Area where both childhood circumstances and current conditions are included. c Area where potential effects of current conditions can be elucidated